 |
DoD
Transitioning to New ACAM2000 Smallpox Vaccine
In early 2008, DoD is
transitioning from Wyeth’s Dryvax brand of smallpox vaccine to Acambis’ ACAM2000 brand of smallpox vaccine. ACAM2000 is a vaccine licensed and approved by
the FDA for protection against smallpox.
Maintaining optimum health and well-being of Service members is our top
priority. Smallpox disease is contagious, deadly, and would disrupt
military readiness. Smallpox vaccination is the best protection against
the threat of smallpox. The DoD’s smallpox vaccination program is part of
our national defense strategy to safeguard Americans against a biological
attack.
The current DoD policy remains unchanged, smallpox vaccinations are still mandatory for those in higher risk areas.
- NEWS
- POLICIES - SERVICE MESSAGES
- DoD
- Department of Defense Participation in
ACAM2000™ Smallpox Vaccine
Post-Marketing 15 Apr 08
- Army
- DOD'S TRANSITION TO ACAM2000 BRAND OF
SMALLPOX VACCINE 14 Feb 08
- Navy
- TRANSITION FROM CURRENT DRYVAX SMALLPOX
VACCINE TO ACAM2000 SMALLPOX VACCINE 27 Feb 08
- Air Force
- Transition to ACAM2000 Smallpox
Vaccine 31 Jan 08
- Coast Guard
- COAST GUARD SMALLPOX VACCINE PROGRAM UPDATE - TRANSITION FROM
DRYVAX TO ACAM2000
30 Jan 08
- PLANNING DOCUMENTS
- SUPPLY AND LOGISTICS
- MMQC-08-1072
WYETH / DISPOSITION INSTRUCTIONS FOR DRYVAX BRAND OF SMALLPOX VACCINE (SMA) / INFORMATION BULLETIN
15 Feb 08
- MMQC-08-1036
IMPLEMENTATION INSTRUCTIONS FOR TRANSITION TO ACAM2000 IN THE DEPARTMENT OF
DEFENSE SMALLPOX VACCINATION PROGRAM 28 Jan 08
- MMQC-07-1380
SMALLPOX VACCINE EXTENSION OF DATING FOR VARIOUS LOTS 27 Dec
07
- QUESTIONS AND ANSWERS
- EDUCATIONAL PRODUCTS
- FOOD AND DRUG ADMINISTRATION
|
|
